利拉鲁肽联合德谷胰岛素对肥胖2型糖尿病患者血糖、血脂及微炎症的影响

Effect of Liraglutide combined with Insulin Degludec on blood glucose,blood lipid and microinflammation in obese patients with type 2 diabetes mellitus

目的探究利拉鲁肽联合德谷胰岛素对肥胖2型糖尿病(T2DM)患者血糖、血脂及微炎症的影响。方法选取2020年12月至2022年12月的九江市第一人民医院收治的72例肥胖T2DM患者作为研究对象,采用随机数字表法将其分为对照组(36例)和研究组(36例)。对照组患者采用德谷胰岛素注射液治疗,研究组患者采用德谷胰岛素注射液联合利拉鲁肽注射液治疗,两组患者均连续治疗3个月。比较两组患者的临床疗效、体重指数(BMI)、血糖指标[空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)]、血脂指标[总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)]、微炎症指标[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)、淀粉样蛋白A(SAA)]和不良反应的发生情况。结果研究组的治疗总有效率高于对照组,差异有统计学意义(P<0.05);研究组治疗后的BMI和FPG、2 h PG、HbA1c均低于对照组,差异有统计学意义(P<0.05);研究组治疗后的TC、TG、LDL-C均低于对照组,HDL-C高于对照组,差异有统计学意义(P<0.05);研究组治疗后的IL-6、TNF-α、hs-CRP、SAA均低于对照组,差异有统计学意义(P<0.05);两组患者的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论对肥胖T2DM患者应用利拉鲁肽联合德谷胰岛素治疗,可改善其血糖、血脂指标,缓解临床症状,降低BMI,利于减轻机体微炎症状态,促进病情改善,提高治疗效果,且安全性较高。

Objective To explore the effect of Liraglutide combined with Insulin Degludec on blood glucose,blood lipid and microinflammation in obese patients with type 2 diabetes mellitus(T2DM).Methods A total of 72 obese patients with T2DM admitted to Jiu Jiang NO.1 People's Hospital from December 2020 to December 2022 were selected as the research objects,and they were divided into control group(36 cases)and study group(36 cases)by random number table method.Patients in the control group were treated with Insulin Degludec Injection,and patients in the study group were treated with Insulin Degludec Injection combined with Liraglutide Injection.Both groups were treated for 3 months.The clinical efficacy,body mass index(BMI),blood glucose indexes(fasting plasma glucose[FPG],2-hour postprandial plasma glucose[2 h PG],glycosylated hemoglobin[HbA1c]),blood lipid indexes(total cholesterol[TC],high density lipoprotein cholesterol[HDL-C],low density lipoprotein cholesterol[LDL-C],triglyceride[TG]),microinflammatory indexes(interleukin-6[IL-6],tumor necrosis factor-α[TNF-α],hypersensitive C-reactive protein[hs-CRP],serum amyloid A[SAA])and adverse reactions.Results The total effective rate of the study group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the BMI,FPG,2 h PG and HbA1c of the study group were lower than those of the control group,and the differences were statistically significant(P<0.05).After treatment,the TC,TG and LDL-C of the study group were lower than those of the control group,and the HDL-C was higher than that of the control group,and the differences were statistically significant(P<0.05).The levels of IL-6,TNF-α,hs-CRP and SAA in the study group after treatment were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion The application of Liraglutide combined with Insulin Degludec in the treatment of obese patients with T2DM can improve their blood glucose and blood lipid indexes,relieve clinical symptoms,reduce BMI,help to reduce the body's micro-inflammatory state,promote the improvement of the condition,improve the treatment effect,and has high safety.